COLLEGIUM PHARMACEUTICAL INC
COLLNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $21.43 β $50.79
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 31.1M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $781M
- Last Q Revenue
- $216M
- P/E Ratio
- 20.3
- P/S Ratio
- 0.9x
- EPS (TTM)
- $1.20
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β1.0%
COLLEGIUM PHARMACEUTICAL INC
COLLAbout COLLEGIUM PHARMACEUTICAL INC
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates
News unavailable.